Vaccine: FluLaval
Company: GlaxoSmithKline
Approval Date: July 20
Protects Against: Influenza

GlaxoSmithKline's ($GSK) influenza vaccine, FluLaval, ranks second among the top-selling flu vaccines of 2012. The product brought in an estimated $375 million last year, second only to Sanofi Pasteur's Fluzone, which grossed about $1.34 billion. The product is approved for use in those 18 and older. For the 2012-2013 flu season--one that began early and is spreading quickly--GSK produced 20 million doses of the vaccine. So far, the company says it is not experiencing shortages. The FDA first granted approval of FluLaval back in 2006.

For more:
Special Report: Top 10 selling flu vaccines of 2012
FDA approves 6 flu vaccines
Flu vaccine, Tamiflu shortage as influenza sweeps U.S.


Suggested Articles

Sanofi lost an appeal challenging the ban on its dengue vaccine Dengvaxia in the Philippines, despite an ongoing outbreak there.

After countless headlines from a Dengvaxia safety scandal in the Philippines, officials are now considering using the Sanofi vaccine again.

Merck's oncology superstar Keytruda has been stealing the spotlight, but in vaccines, the drugmaker has growth figures to tout.